Global Cancer Technology, Inc possesses an incredible array of medical technologies that can produce exceptional returns to investors when commercialized. To accomplish this, the Company has been conducting a Private Placement of its shares under a Reg D offering limited to accredited investors. The Company will continue with this offering and use the proceeds to launch a Red A+ offering.
The Company received SEC qualification for its Reg A+ registration in December of 2018 with a share offering price of $3 per share. The Company intends to raise approximately $5Million through this offering.
Qualified investors can receive information on this offering by contacting the Company